


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



DAWNRAYS PHARMACEUTICAL (HOLDINGS) LIMITED

東瑞製藥(控股)有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2348)

DATE OF BOARD MEETING

AND

PROPOSED DECLARATION OF SPECIAL DIVIDEND

The board of directors (the “Board”) of Dawnrays Pharmaceutical (Holdings) Limited (the “Company”) hereby announces that a meeting of the Board will be held at Units 3001-02, 30/F, CNT Tower, 338 Hennessy Road, Wanchai, Hong Kong on Wednesday, 11 July 2018 for the purpose of considering the recommendation on the payment of a special dividend.

The Company will make a further announcement after the Board meeting to set out the details of the special dividend, if approved by the Board.

As the proposed special dividend may or may not be approved by the Board at the Board meeting, shareholders and potential investors of the Company should exercise caution in dealing in the securities of the Company.

By Order of the Board
Dawnrays Pharmaceutical (Holdings) Limited
Pang Kit Ling
Company Secretary

Hong Kong, 27 June 2018

As at the date of this announcement, the Board of the Company comprises three executive directors, namely Ms. Li Kei Ling, Mr. Hung Yung Lai and Mr. Chen Shaojun; one non-executive director, namely Mr. Leung Hong Man; and three independent non-executive directors, namely Mr. Lo Tung Sing Tony, Mr. Ede, Ronald Hao Xi and Ms. Lam Ming Yee Joan.

**for identification purpose only*